Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded at TD Cowen

TD Cowen upgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a hold rating to a buy rating in a research note issued to investors on Monday, MarketBeat Ratings reports. They currently have $8.00 target price on the stock.

Other equities analysts have also issued research reports about the stock. Wells Fargo & Company started coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, September 11th. They set an “overweight” rating and a $4.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 1st. Finally, Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Milestone Pharmaceuticals Stock Performance

Shares of NASDAQ MIST opened at $2.15 on Monday. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $3.06. The firm has a market cap of $183.12 million, a P/E ratio of -2.62 and a beta of 0.41. The stock has a fifty day moving average price of $2.19 and a two-hundred day moving average price of $1.92. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. Research analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current fiscal year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Propel Bio Management LLC acquired a new stake in shares of Milestone Pharmaceuticals in the first quarter worth $1,161,000. Walleye Capital LLC acquired a new position in Milestone Pharmaceuticals during the first quarter valued at $74,000. Simplify Asset Management Inc. lifted its stake in Milestone Pharmaceuticals by 16.5% in the 2nd quarter. Simplify Asset Management Inc. now owns 990,000 shares of the company’s stock worth $1,921,000 after acquiring an additional 140,000 shares in the last quarter. Valeo Financial Advisors LLC lifted its stake in Milestone Pharmaceuticals by 553.5% in the 2nd quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock worth $254,000 after acquiring an additional 110,699 shares in the last quarter. Finally, Bay Rivers Group acquired a new stake in Milestone Pharmaceuticals during the 2nd quarter worth about $28,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.